VelaTel Global Communications, Inc. (OTCQB: VELA) (PINK: VELA) reached up 15.38% in morning trading to $.12 with 2.5M shares traded. VelaTel Global Communications, Inc. ("VelaTel") acquires spectrum assets through acquisition or joint ventures. VelaTel provides capital, engineering, architectural and construction services related to the build-out of wireless broadband telecommunications networks, which it then operates by offering services attractive to residential, enterprise and government subscribers. VelaTel currently focuses on emerging markets where Internet penetration rate is low relative to the capacity of incumbent operators that provide comparable cutting-edge services, and/or where the entry cost to acquire spectrum is low relative to projected subscribers. VelaTel currently has project operations in People's Republic of China and Peru. Additional target markets include countries in Latin America, the Caribbean, Southeast Asia and Eastern Europe. VelaTel Global Communications, Inc. (OTCQB: VELA.PK - News) (Pinksheets: VELA.PK - News) announced today that its 95% owned subsidiary, Perusat, operator of Peru's first 4G broadband network under the trade name "GO MOVIL," has begun generating revenue from prepaid subscribers of its Internet service plans.
Galena Biopharma (Nasdaq:GALE) reached up 25.49% in morning trading to $.64 with 120K shares traded. Galena Biopharma, Inc. is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena Biopharma (Nasdaq:GALE) today announced a clinical development collaboration with Genentech/Roche and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) to develop NeuVax(TM) (E75) in combination with Herceptin(R) (trastuzumab; Genentech/Roche) in adjuvant breast cancer patients currently not eligible for Herceptin therapy.
OXiGENE, Inc. (Nasdaq:OXGN) reached up 12.90% in morning trading to $1.05 with 120K shares traded. OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients. OXiGENE, Inc. (Nasdaq:OXGN - News) announced today that it has signed a purchase agreement for the sale, from time to time, of up to $20 million of its common stock with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor. The proceeds from any sales under this purchase agreement will be used to advance OXiGENE's late and early-stage clinical pipeline.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com:
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
